| Page | File |
| 2000 | |
| 2001 | |
| 2002 | |
| 2003 | |
| 2004 | |
| 2005 | |
| 2006 | |
| 2007 | |
| 2008 | |
| A New Paradigm in Pediatric Drug Development: The Application of Cognitive Engineering | Poster_Chris_Rubino_v2_97_2.pdf |
| A New Paradigm of Real-Time Data Assembly to Support Knowledge-Based Decision Making: A Case Study | DIAposter_97PPTver4.pdf |
| A Novel Application of Monte Carlo Simulation to Compare PK-PD Target Attainment Rates for Oral Time-Dependent Antimicrobial Regimens | ICAAC2002_Abs_640.pdf |
| A novel approach for evaluating the microbiological efficacy of Tigecycline in patients with complicated skin and skin-structure infections | ECCMID_2005_cSSSIcohorts_posterP1183-1.pdf |
| A Novel Pharmacodynamic Model for Gatifloxacin vs. Salmonella typhi in Timed Kill Curves | CPT2004i.pdf |
| AAPS 1996 | |
| AAPS 1999 | |
| AAPS 2000 | |
| AAPS 2001 | |
| AAPS 2002 | |
| AAPS 2003 | |
| AAPS 2004 | |
| AAPS 2005 | |
| AAPS 2006 | |
| AAPS 2007 | |
| ACCP 2002 | |
| ACoP 2008 | |
| An Electronic Strategy for Implementing a New Paradigm in Pediatric Drug Development | dia.rtdc.pdf |
| An Historical Review of the Incorporation of UGT 1A1 Genotype in Population of UGT 1A1 Genotype in Population Analyses of Atazanav | 2004.AAPS.Cirincione.Roundtable.pdf |
| Antimicrobial Surveillance Programs: Can these Databases be Helping in Identifying Relationships Predictive of Resistance and be Applied to Patient Care? | IDSA-2003oct13.pdf |
| Application of Real-Time Data Assembly (RTDA) to a Pivotal Phase III Pediatric Trial: A Proactive Approach to Population Pharmacokinetic/Pharmacodynamic (PK/PD) Dataset Creation | rtda-ascpt2003-poster-2003mar28.pdf |
| ASA 2004 | |
| ASCO 2004 | |
| ASCO 2005 | |
| ASCO 2006 | |
| ASCO 2007 | |
| ASCPT 2002 | |
| ASCPT 2003 | |
| ASCPT 2004 | |
| ASCPT 2006 | |
| ASCPT 2007 | |
| ASCPT 2008 | |
| Blood Management and Infections in Cardiovascular and Orthopedic Surgery | asa2004.poster.v1.2004sep01-1.pdf |
| Change-Point Models: Some Considerations in Implementation | ECPAG02-Chgpt-model.pdf |
| Characterization of Oritavancin Pharmacokinetics (PK) in Plasma and Blister Fluid in Nornam Healthy Volunteers | ICAAC2003-poster.2003sep10.pdf |
| Cognigen Corporation - Posters and Presentations | |
| Cognitive Engineering - The Tools, Mindset, and Strategy for Integrated Development | cog.eng.posterv2.pdf |
| Collegium Internationale Neuro-Psychopharmacologicum (CINP) 1998 | |
| Comparison of Censored Regression (CR) vs. Standard Regression (SR) Analyses for Modeling Relationships Between Minimum Inhibitory Concentrations (MIC) and Patient- and Institution-Specific Variables | arrest-ascpt2003-poster-2003mar28.pdf |
| Comparison of Laboratory Safety Data from Japanese and Non-Japanese in Linezoliid Phase I Studies | poster_lzd_2002mar11_133_.pdf |
| Comparison of Linezolid Pharmacokinetics (PK) from Phase I Studies of Japanese and Caucasians | poster_bridgingPK_Mar2002_v2_132_.pdf |
| Comparison of Parametric (NONMEM) and Non-Parametric (NPEM) Methods for Population Pharmacokinetic (PK) Modeling of Bi-Model Populations | nonmem-npem-aaps2003_2003oct22.pdf |
| Comparison of Post-Operative Nosocomial Infection Associated with Blood Management Techniques in Cardiovascular and Orthopedic Surgery | poster.v1.2002OCT09.pdf |
| Development of a Novel Population Pharmacokinetic (PK)-Based Method to Describe the Time-Course of Gatifloxacin (GAT) Middle Ear Fluid (MEF) Concentrations in Children | |
| Development of a Pharmacokinetic (PK) Model and Assessment of Patient (PT) Covariate Effects on Dose-Dependent PK following Different Dosing Schedules in Two Phase I Trials of AP23573 (AP), an mTOR Inhabitor | ASCO-pk_poster_final_2005May10.pdf |
| DIA 2000 | |
| DIA 2001 | |
| DIA 2002 | |
| DIA 2003 | |
| DIA 2004 | |
| Diagnosing Problems with Ka Estimation Due to Sparse Sampling | scott-ecpag2002.pdf |
| ECCMID 2003 | |
| ECCMID 2004 | |
| ECCMID 2005 | |
| ECCMID 2006 | |
| ECPAG 2002 | |
| Effect of Hepatic Impairment on the Pharmacokinetics of the Novel Glycopeptide Oritavancin | AAPS2004-ORI-HepaticImp-Poster.2004oct27.pdf |
| Effect of Lifestyle Intervention on the Placebo Response in Anti-Obesity Trials: Considerations for Exposure-Response Modeling | Ascpt2007_amylin_2007mar13.pdf |
| Efficacy of Bupropion SR on Reducing Craving in Smoking Cessation | scotland.poster.V3.pdf |
| ERS 2006 | |
| Estimation of In VitroSusceptibility Breakpoints for Tigecycline Against Enterobacteriaceae | ICAAC_TAR_Ecoli_092005_3.pdf |
| Estimation of In VitroSusceptibility Breakpoints for Tigecycline Against Staphylococcus aureus | ICAAC_TAR_Staph_091305_2.pdf |
| Evaluation of Covariate Effects on Population Pharmacokinetics (PPK) of Both Parent Drug and Metabolite(s) from Clinical Trial Data without Metabolite Administration or Excretion Sampling | AAPS2002poster_v6.2002oct29.pdf |
| Evaluation of the Bias and Precision of Bayesian Parameter Estimates When Applying a Phase I Model to Sparse Patient Data | AAPS_poster_2004nov01.pdf |
| Evaluation of the Relationship Between Sumanirole Exposure and Orthostatic Hypotension | 3022_AAPS.pdf |
| Exposure-Response Analysis of the Efficaccy of Tigecycline in Patients with complicated skin and skin-structure infected infections | ECCMID_2005_cSSSI_ER_poster1.pdf |
| Exposure-Response Analysis of the Efficacy of Tigecycline in Patients with Complicated Intra-Abdominal Infections (cIAI) | ICAAC_tig_pkpd_ia_13sep2005_1.pdf |
| Exposure-Response Relationship for Nebulized Arformoterol in Subjects with COPD | ERS_pd_poster_v4_2006aug24.pdf |
| Factors Influencing the Pharmacokinetics (PD) of Anticancer Drug Irinotecan (CPT-11) and its Major Metabolites, SN-38 and SN38G | cpt11-poster-2002sep16.pdf |
| Gatifloxacin and the Elderly: PK-PD Rationale for Potential Age-Related Dose Reduction | |
| Gatifloxacin Exposure in Maxillary Sinus and Middle Ear – All Sites of Infection Are Not Created Equal | IDSA_Sinusitis_MEF_Poster_2003oct01.pdf |
| Gatifloxacin in Children with Recurrent Otitis Media (ROM): Application of Real-Time Data Assembly (RTDA) and Sparse PK Sampling in Clinical Development | |
| IARS 2004 | |
| ICAAC 2000 | |
| ICAAC 2001 | |
| ICAAC 2002 | |
| ICAAC 2003 | |
| ICAAC 2004 | |
| ICAAC 2005 | |
| IDSA 2002 | |
| IDSA 2003 | |
| IDSA 2005 | |
| Impact of Pharmacokinetic and Microbiological Variability on the Pharmacodynamics of Gatifloxacin against S. pneumoniae in Children | |
| Implementation of Concentration Dependent 'First-Pass' Models using NONMEM | 1996_aaps_luann_pnu.pdf |
| Improving the Efficiency and Ensuring the Quality of Data Assembly for Pharmacometric Analysis | ACoP_poster_2008feb.pdf |
| Influence of Dose Size on Dose Response Relationships for Linezolid Efficacy Using Monte Carlo Simulations | monteposter.v2.pdf |
| Influence of Estimation of Inter-Occasion Variability on Detection of Time-Varying Covariates | AAPS_2007_poster.pdf |
| Integrating Real-Time Data Assembly (RTDA) and Population Pharmacokintics as Tactical Components of Cognitive Engineering | Poster_MaryEileen_McPhee_v2_97_2.pdf |
| Integration of Pharmaceutical Product Development in Asia/Japan Into the Global Program | tgrasel1_20_.pdf |
| Internet Based Communication Strategies to Support Linezolid Bridging Programs During Global Drug Development | tgrasel3_22_.pdf |
| Lack of Significant Drug Interactions for Sumanirole in Phase II Studies Using Population Pharmacokinetic (PPK) Methods | 3021_AAPS.pdf |
| Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Hepatoprotective Effect of Dexamethasone on Transient Transaminitis After Trabectedin (ET-743, Yondelis®) Treatment | ASCO-2007.pdf |
| Minimum Efficacy and Mutation Prevention Exposure Target Attainment Rates Against Streptococcus pneumoniae for Levofloxacin 500 mg and 750 mg and Moxifloxacin 400 mg | |
| Model Feasibility Assessment as a Driver for Model Based Drug Development | ascpt_MFA_poster_2008apr02.pdf |
| Model-Based Evaluations to Select and Confirm Doses in the Clinical Development of Exenatide | ASCPT_2007 _FinemanPoster_v4.pdf |
| Modeling & Simulation Learn to Speak the Language: Modeling | aaps_cirincione_2006oct31-1.pdf |
| Monte Carlo Simulation and New Cefotaxime, Ceftriaxone, and Cefepime Susceptibility Breakpoints for S. pneumoniae, Including Strains with Reduced Susceptibility to Penicillin | |
| Monte Carlo Simulation to Estimate in VITRO susceptibility breakpoints for Moxifloxacin, Gatifloxacin, and Levofloxacin against Staphylococcus Aureus | Moxi SA BP Poster_ICAAC 2004.pdf |
| Noncompartmental Pharmacokinetics of Tigecycline in Phase 3 Studies of Patients with Complicated Skin and Skin-Structure and Intra-Abdominal Infections | Icaac_noncomp_v4_2005sep06_sent.pdf |
| PAGE 2007 | |
| Pharmacodynamic Characterization of NVP-LMB415 against Haemophilus influenzae in an In Vitro Hollow-Fiber System | P901.ECCMID.2005mar23-final.pdf |
| Pharmacodynamic Comparisons of Different Dosing Regimens of Penicillin G Against Penicillin-Susceptible and -Resistant Pneumococci | |
| Pharmacodynamics of Gatifloxacin 400 mg, Levofloxacin 500 mg and 750 mg and Moxifloxacin 400 mg Against Ciprofloxacin-Resistant Streptococcus pneumoniae | |
| Pharmacogenomic and Pharmacokinetic Assessment of Liposome Encapsulated SN-38 (LE-SN38) in Advanced Cancer Patients | ASCO_2004-1.pdf |
| Pharmacokinetic Analysis of Gatifloxacin in Plasma and Sinus Aspirate During Treatment of Acute Maxillary Sinusitis | draft2-AAPS.pdf |
| Pharmacokinetic/Pharmacodynamic (PK/PD) Model for the Safety of Tigecycline (T) in Patients with Complicated Intra-Abdominal Infections (cIAI) | ECCMID_2006mar24.pdf |
| Pharmacokinetic/Pharmacodynamic (PK/PD) Model for Tolvaptan in Healthy Subjects | ASCPT_v1_2006mar03.pdf |
| Pharmacokinetic/Pharmacodynamic Analysis of Data from a Phase III Trial of Linezolid IV/PO for the Treatment of Resistant Gram-Positive Bacterial Infections in Children | ASCPT2003MAR26_Minh.pdf |
| Pharmacokinetic/Pharmacodynamic Model for the Safety of Tigecycline in Patients with Complicated Skin and Skin-Structure Infections | IDSA_v4_2005nov02.pdf |
| Pharmacokinetic/Pharmacodynamic model for the tolerability of Tigecycline in healthy volunteers | ECCMID_2005_tigecycline.pdf |
| Pharmacokinetics (PK) of Tigecycline (TG) in Healthy Adult Volunteers and in Subjects with Renal Impairment | Meagher ECCMID 2004 PK in Renal Impairment final poster.pdf |
| Pharmacokinetics/Pharmacodynamics in Otitis Media: Comparison of Time-Dependent Antibiotics in Middle Ear Fluid | IDSA_PK-PD_in_Otitis_Media_in2000_v1_2002oct23.pdf |
| PharmaSUG 2002 | |
| Phase III Population Pharmacokinetics and Pharmacodynamics of Azimilide | azim.pdf |
| PK- PD Evaluation of Doripenem (DOR) Against Extended Spectrum ß- Lactamase (ESBL) Producing Enterobacteraceae | Andes_poster.pdf |
| PK-PD Target Attainment with Monte Carlo Simulation as Decision Support of Phase 2 / 3 Dosing Strategies for the Clinical Development of Doripenem | Cognigen-PK-PD-Final.pdf |
| Population Modeling to Guide Phase 3 Dose Selection for AC2993 (Synthetic Exendin-4) | Poster_Exendin_2002mar19.pdf |
| Population Pharmacodynamic (PD) Assessment of Linezolid Efficacy in Community Acquired Pneumonia, Skin and Soft Tissue Infections, and Bacteremia | phaseIIpd-slides-V3.00.09.18.pdf |
| Population Pharmacodynamic (PD) Assessment of the Safety and Antiretrovial Activity of Atazanavir (BMS-232632) | ICAAC_2001_BMS_232632.pdf |
| Population Pharmacodynamic Assessment of Atazanavir (BMS-232632) Exposure, Genotype, and Safety | C674.pdf |
| Population Pharmacokinetic (PK) Analysis of Gatifloxacin in Pediatric Patients | |
| Population Pharmacokinetics (PK and Pharmacodynamics (PD) of Gatifloxacin (GAT) Plasma and MIddle Ear Fluid (MEF) Concentrations in Pediatric Patients with Acute Otitis Media Treatment Failures (AOM-TF) and/or Recurrent Otitis Media (ROM) | |
| Population Pharmacokinetics (PK) of Linezolid in Neonates and Young Infants | Final_poster2.pdf |
| Population Pharmacokinetics (PK) of Linezolid in Patients with Community-Acquired Pneumonia (CAP) and Skin and Soft Tissue (SST) Infections | jb500.pdf |
| Population Pharmacokinetics of (R)-Albuterol Following Inhaled Levalbuterol or Racemic Albuterol via a Hydrofluoroalkane Metered Dose Inhaler in Pediatric and Adult Asthma Patients | AAPS_202152_xopenex_aaps2006_v3_2006oct24_sent.pdf |
| Population Pharmacokinetics of Bendamustine and Metabolites in Patients with Indolent Non-Hodgkin Lymphoma | ascpt_poster_2008mar06.pdf |
| Population Pharmacokinetics of Doripenem | dori-poppk-ICAAC2004.pdf |
| Population Pharmacokinetics of Modafinil Film-Coated Tablets in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder | AAPS_Owens_Fin_2005.pdf |
| Population Pharmacokinetics of Nebulized Arformoterol in Subjects with COPD | ERS_pk_poster_v4_2006aug24.pdf |
| Population Pharmacokinetics of Paliperidone ER in Healthy Subjects and Patients with Schizophrenia | ASCPT_v2_2007mar15.pdf |
| Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-abdominal or Skin and Skin-Structure Infections | 2276_tgc_ppkph3_aaps_v4_2005oct31_sent.pdf |
| Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-abdominal or Skin and Skin-Structure Infections | 2276_tgc_poppkph2_icaac_v4_2005dec09.pdf |
| Population Pharmacokinetics of Tigecycline in Phase 1 Subjects | ICAAC4_ph1_po__PK_Vrs2Reduc_1.pdf |
| Population Pharmacokinetics/Pharmacodynamics (PK/PD) of Antidepressant R, R(-) and S, S(+) Reboxetine (RBX) | pkpd_poster_2001oct11.pdf |
| Population PK/PD for Managers: From Identifying and Maximizing the Value-Add to Considerations for Implementation | Fiedler-Kelly_PopPKPD4mgrs.pdf |
| Postoperative Infection Rate Following Cardiac Surgery with Allogeneic vs. other Blood Management Techniques | SABM2004.poster.v1.2004sep02.pdf |
| Practical Approaches to Utilizing Exposure-Response Relationships to Inform Drug Development and Prescribing Decision-Making | 03001_CR4_Grasela_Ted_V1.pdf |
| Pre-2000 | |
| Pre-2006 | |
| Publications 2001 | |
| Publications 2002 | |
| Publications 2003 | |
| Publications 2004 | |
| Publications 2005 | |
| Publications 2006 | |
| Publications 2007 | |
| Publications 2008 | |
| Publications Pre-2000 | |
| Publications- Pre-2000 - 2005 | |
| Rapid Assessment of Dataset Structures | DM06_Cognigen.pdf |
| Relationship Between Increased Levofloxacin Use and Decreased Susceptibility of Streptococcus pneumoniae : Report From the ARREST Program | Rel_Btwn_Levofloxacin_poster_2003sep10.pdf |
| Relationships Between Susceptibility of Enterobacter spp. and Hospital- and Patient-Specific Variables: Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program) | SMBhavnani.P1035.Enterobacter.ECCMID.2003.pdf |
| Relationships Between Susceptibility of Pseudomonas aeruginosa and Hospital- and Patient-Specific Variables: Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program) | SMBhavnani.P1037.P.aeruginosa.ECCMID.2003.pdf |
| Relationships Between Susceptibility of Streptococcus pneumoniae against Levofloxacin & Hospital- & Patient-Specific Variables: Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program) | SMBhavnani.ARREST.S.pneumoniae_levo.IDSA2002.poster.pdf |
| Relationships Between Susceptibility of Streptococcus pneumoniae and Hospital- and Patient-Specific Variables: Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program) | SMBhavnani.P1036.S.pneumoniae.ECCMID.2003.pdf |
| SABM 2004 | |
| Serial Sinus Aspirate Sampling (SSAS): A Novel Technique for Evaluating Antimicrobial Therapy of Acute Maxillary Sinusitis (AMS) | Sinusitis_Poster.2003sep02.pdf |
| Simultaneous Population Pharmacokinetic (PPK) Modeling of Irinotecan (CPT-11) and its Major Metabolites, SN-38 and SN-38G | CPT11_2002mar19.pdf |
| The Application of Monte Carlo Simulation to the Estimation of Susceptibility Breakpoints | ICAAC_2002_Abs_1020.pdf |
| The Application of Systematic Analysis for Identifying and Addressing the Needs of the Pharmacometric Process | PAGE_poster_Ted_2007may31.pdf |
| The Impact of Mivacurium and Rocuronium on Recovery Times in Ambulatory Anesthesia Procedures | Poster_IARS_2004mar18.pdf |
| The Implementation of Population PK/PD in Pediatric Drug Development | AAPS_Pediatric_Pop_Grasela_2003Oct27V2.pdf |
| The Role of Exposure-Response Evaluations in Global Drug Development | DIA_2004June16_Grasela_Ted_V1.pdf |
| The Role of Population PK/PD Analysis During the Implementation of a Bridging Strategy for Linezolid | tgrasel2.pdf |
| Time Course Distributions of Laboratory Indices: A strategy for Evaluating Laboratory Data from Clinical Trials | jb282.pdf |
| Transcend Global and Corporate Boundaries During Drug Development | Poster_Darcy_Foit_97.pdf |
| Uniqueness of Solutions to Compartmental Models of Population Pharmacokinetics for Drugs Ungergoing Complex Metabolism | Uniqueness_Mar2002.pdf |
| Use of an in vitro Pharmacodynamic Model & Monte Carlo Simulation to Characterize the Pharmacokinetics and Pharmacodynamics of Gatifloxacin vs Salmonella Typhi | ECCMID-poster-2004apr26.pdf |
| Use of Monte Carlo Simulation to Evaluate the Antibacterial Activity of Garenoxacin Against Gram-Positive Bacteria | |